Abstract
Photodynamic therapy (PDT) has become a standard, routine procedure in dermatology over the past several years. Most clinicians have found that by utilizing PDT, many dermatologic conditions can be successfully treated. This article will review the experience with aminolevulinic acid (Levulan®) PDT, including the clinical trials that led to US FDA approval for the treatment of nonhyperkeratotic actinic keratoses of the face or scalp and other studies showing its versatility in the treatment of various dermatologic diseases. Finally, best practice guidelines for utilizing aminolevulinic acid PDT in the clinic will be proposed.
Financial disclosure
Michael Gold is a consultant to Dusa Pharmaceuticals, performs research, speaks on their behalf, receives honoraria and travel expenses and is a stock owner. Gold is a medical advisory board member of Lumenis Inc., performs research, speaks on their behalf, receives honoraria and travel expenses and is a stock owner. Gold is also a consultant for Alma Lasers, Cynsoure, Aerolase, Aesthera, Sciton, speaks on their behalf and performs research.
Notes
*Common indications for 5-aminolevulinic acid photodynamic therapy in the USA.
*Devices used by author; other settings from recognized experts in the laser field. IPL: Intense pulsed light; PDL: Pulsed dye laser.